1
|
Jemal A, Siegel R, Xu J and Ward E: Cancer
Statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar
|
2
|
Wolfson AH, Sightler SE and Markoe AM: The
prognostic significance of surgical staging for carcinoma of the
endometrium. Gynecol Oncol. 45:142–146. 1992. View Article : Google Scholar : PubMed/NCBI
|
3
|
Kamat AA, Merritt WM, Coffey D, et al:
Clinical and biological significance of vascular endothelial growth
factor in endometrial cancer. Clin Cancer Res. 13:7487–7495. 2007.
View Article : Google Scholar : PubMed/NCBI
|
4
|
Kowanetz M and Ferrara N: Vascular
endothelial growth factor signaling pathways: therapeutic
perspective. Clin Cancer Res. 12:5018–5022. 2006. View Article : Google Scholar : PubMed/NCBI
|
5
|
Ortega J, Vigil CE and Chodkiewicz C:
Current progress in targeted therapy for colorectal cancer. Cancer
Control. 17:7–15. 2010.PubMed/NCBI
|
6
|
Koutras AK, Fountzilas G, Makatsoris T,
Peroukides S and Kalofonos HP: Bevacizumab in the treatment of
breast cancer. Cancer Treat Rev. 36:75–82. 2010. View Article : Google Scholar : PubMed/NCBI
|
7
|
Tamaskar I and Pili R: Update on novel
agents in renal cell carcinoma. Expert Rev Anticancer Ther.
9:1817–1827. 2009. View Article : Google Scholar : PubMed/NCBI
|
8
|
Norden AD, Drappatz J and Wen PY:
Antiangiogenic therapies for high-grade glioma. Nat Rev Neurol.
5:610–620. 2009. View Article : Google Scholar : PubMed/NCBI
|
9
|
Watanabe K, Hasegawa Y, Yamashita H, et
al: Vasohibin as an endothelium-derived negative feedback regulator
of angiogenesis. J Clin Invest. 114:898–907. 2004. View Article : Google Scholar : PubMed/NCBI
|
10
|
Kimura H, Miyashita H, Suzuki Y, et al:
Distinctive localization and opposed roles of vasohibin-1 and
vasohibin-2 in the regulation of angiogenesis. Blood.
113:4810–4818. 2009. View Article : Google Scholar : PubMed/NCBI
|
11
|
Xue X, Gao W, Sun B, et al: Vasohibin 2 is
transcriptionally activated and promotes angiogenesis in
hepatocellular carcinoma. Oncogene. May 21–2012.(Epub ahead of
print).
|
12
|
Takahashi Y, Koyanagi T, Suzuki Y, et al:
Vasohibin-2 expressed in human serous ovarian adenocarcinoma
accelerates tumor growth by promoting angiogenesis. Mol Cancer Res.
Jul 23–2012.(Epub ahead of print).
|
13
|
Kuramoto H, Tamura S and Notake Y:
Establishment of a cell line of human endometrial adenocarcinoma in
vitro. Am J Obstet Gynecol. 114:1012–1019. 1972.PubMed/NCBI
|
14
|
Suzuki M, Kuramoto H, Hamano M, Shirane H
and Watanabe K: Effects of oestradiol and progesterone on the
alkaline phosphatase activity of a human endometrial cancer
cell-line. Acta Endocrinol (Copenh). 93:108–113. 1980.PubMed/NCBI
|
15
|
Nishida M: The Ishikawa cells from birth
to the present. Hum Cell. 15:104–117. 2002. View Article : Google Scholar : PubMed/NCBI
|
16
|
Miyagishi M and Taira K: Strategies for
generation of an siRNA expression library directed against the
human genome. Oligonucleotides. 13:325–333. 2003. View Article : Google Scholar : PubMed/NCBI
|
17
|
Yamamoto O, Hamada T, Tokui N and Sasaguri
Y: Comparison of three in vitro assay systems used for assessing
cytotoxic effect of heavy metals on cultured human keratinocytes. J
UOEH. 23:35–44. 2001.PubMed/NCBI
|
18
|
Suzuki Y, Kobayashi M, Miyashita H, Ohta
H, Sonoda H and Sato Y: Isolation of a small vasohibin-binding
protein (SVBP) and its role in vasohibin secretion. J Cell Sci.
123:3094–3101. 2010. View Article : Google Scholar : PubMed/NCBI
|
19
|
Hanahan D and Weinberg RA: The hallmarks
of cancer. Cell. 100:57–70. 2000. View Article : Google Scholar
|
20
|
Ferrara N: Vascular endothelial growth
factor. Arterioscler Thromb Vasc Biol. 29:789–791. 2009. View Article : Google Scholar
|
21
|
McMeekin DS, Sill MW, Benbrook D, et al
Gynecologic Oncology Group: A phase II trial of thalidomide in
patients with refractory endometrial cancer and correlation with
angiogenesis biomarkers: a Gynecologic Oncology Group study.
Gynecol Oncol. 105:508–516. 2007. View Article : Google Scholar : PubMed/NCBI
|
22
|
Sanseverino F, Santopietro R, Torricelli
M, et al: pRb2/p130 and VEGF expression in endometrial carcinoma in
relation to angiogenesis and histopathologic tumor grade. Cancer
Biol Ther. 5:84–88. 2006. View Article : Google Scholar : PubMed/NCBI
|
23
|
Hirai M, Nakagawara A, Oosaki T, Hayashi
Y, Hirono M and Yoshihara T: Expression of vascular endothelial
growth factors (VEGF-A/VEGF-1 and VEGF-C/VEGF-2) in postmenopausal
uterine endometrial carcinoma. Gynecol Oncol. 80:181–188. 2001.
View Article : Google Scholar : PubMed/NCBI
|
24
|
Cerezo L, Cardenes H and Michael H:
Molecular alterations in the pathogenesis of endometrial
adenocarcinoma. Therapeutic implications. Clin Transl Oncol.
8:231–241. 2006. View Article : Google Scholar : PubMed/NCBI
|
25
|
Saranadasa M and Wang ES: Vascular
endothelial growth factor inhibition: conflicting roles in tumor
growth. Cytokine. 53:115–129. 2011. View Article : Google Scholar : PubMed/NCBI
|
26
|
Korpal M and Kang Y: The emerging role of
miR-200 family of microRNAs in epithelial-mesenchymal transition
and cancer metastasis. RNA Biol. 5:115–119. 2008. View Article : Google Scholar : PubMed/NCBI
|